Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics Inc (AXDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 24,685,998 | $12,342,999 | +3% | 5.94% | |
| 2. | Armistice Capital Steven Boyd | 2,078,000 | $2,493,600 | -2% | 0.03% |
| 3. | Birchview Capital Matthew Strobeck | 325,239 | $390,287 | 0.31% | |
| 4. | Renaissance Technologies Jim Simons | 107,062 | $128,474 | +161% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 35,412 | $42,494 | +184% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 200,000 | Director | 653,224 | 2024-12-03 | Filing | |
| $0.00 | 100,000 | Director | 120,682 | 2024-01-23 | Filing | |
| $0.00 | 13,333 | Director | 20,927 | 2024-01-23 | Filing | |
| $0.00 | 16,666 | Director | 24,260 | 2024-01-23 | Filing | |
| $0.00 | 16,666 | Director | 453,224 | 2024-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.71 | 6,816 | Officer | 64,568 | 2025-04-01 | Filing | |
| $1.09 | 535 | Officer | 51,384 | 2025-02-26 | Filing | |
| $1.35 | 485 | Officer, Director | 163,434 | 2025-02-03 | Filing | |
| $1.57 | 200,000 | Large Shareholder, Director | 8,310,388 | 2024-12-03 | Filing | |
| $0.88 | 86 | Officer | 82,028 | 2024-05-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,292,574 | $1,317,029 | 0.42% | |
| 2. | 12,363,301 | $1,236,000 | 0% | |
| 3. | 1,003,581 | $1,204,297 | 0.14% | |
| 4. | 2,045,144 | $1,182,858 | 0.25% | |
| 5. | 5,283,122 | $1,057,146 | 0.01% |
News See All
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2024 Earnings Call Transcript
Operator: Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Incorporated. First Quarter 2024 Results Conference Call. All participants will be in a listen only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.89 EPS, expectations were $-0.62. Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Third Quarter Results Conference Call. All participant’s will be in listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Q2 Results Conference Call. [Operator Instructions].
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Accelerate Diagnostics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. . I would now like to turn the conference over to Mr.
5 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Billionaire Hedge Funds
